• Citer

Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial.

par Girard, Nicolas;Ponce Aix, S;Cedres, S;Berghmans, Thierry ;Burgers, S;Toffart, Anne-Claire;Phalke, Swati Popat ;Janssens, A;Gervais, R;Hochstenbag, M;Cardoso da Silva, M.;Burger, I A;Prosch, Helmut;Stahel, R;Xenophontos, E;Pretzenbaher, Y;Neven, A;Peters, S.
Référence ESMO Open, 8, 3, page (101576)
Publication Publié, 2023-06

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial.
Auteur:	Girard, Nicolas; Ponce Aix, S; Cedres, S; Berghmans, Thierry; Burgers, S; Toffart, Anne-Claire; Phalke, Swati Popat; Janssens, A; Gervais, R; Hochstenbag, M; Cardoso da Silva, M.; Burger, I A; Prosch, Helmut; Stahel, R; Xenophontos, E; Pretzenbaher, Y; Neven, A; Peters, S.
Informations sur la publication:	ESMO Open, 8, 3, page (101576)
Statut de publication:	Publié, 2023-06
Sujet CREF:	Sciences bio-médicales et agricoles
Mots-clés:	immunotherapy
	thymic carcinoma
	thymoma
MeSH keywords:	Humans
	Male
	Female
	Middle Aged
	Nivolumab -- adverse effects
	Ipilimumab -- adverse effects
	Thymoma -- drug therapy -- chemically induced
	Thymus Neoplasms -- drug therapy -- chemically induced
	Progression-Free Survival
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:2059-7029
	info:doi/10.1016/j.esmoop.2023.101576
	info:pii/S2059-7029(23)00808-6
	info:scp/85161327879
	info:pmid/37285717
	PMC10265606